Dermatol Ther. 2022 Apr 19:e15524. doi: 10.1111/dth.15524. Online ahead of print.
ABSTRACT
BACKGROUND: Recent knowledge on the key role of interleukin (IL)23/17 axis in psoriasis pathogenesis, led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody specifically targeting IL23. Its efficacy and safety were showed by both clinical trials and real-life experiences. However, real life data on effectiveness and safety of risankizumab in patients who previously failed anti-IL17 are scant.
OBJECTIVES: To assess the efficacy and safety of risankizumab in patients who previously failed anti-IL17.
METHODS: A 52-week real-life retrospective study was performed to assess the long-term efficacy and safety of risankizumab in patients who previously failed anti-IL17.
RESULTS: A total of 39 patients (26 male,66.7%; mean age 50.5±13.7years) were enrolled. A statistically significant reduction of Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) was assessed at each follow-up (PASI at baseline vs week52: 13.7±5.8 vs 0.9±0.8,p<0.0001; BSA 21.9±14.6 vs 1.9±1.7,p<0.0001). Nail Psoriasis Severity Index improved as well, being statistically significative only at week16 and thereafter [9.3±4.7 at baseline, 4.1±2.4(p<0.01) at week16, 1.4±0.8(p<0.0001) at week52]. Treatment was discontinued for primary and secondary inefficacy in 1(2.6%) and 3(7.7%) patients, respectively. No cases of serious adverse events were assessed.
CONCLUSION: Our real-life study confirmed the efficacy and safety of risankizumab, suggesting it as a valuable therapeutic weapon among the armamentarium of biologics, also in psoriasis patients who previously failed anti-IL17 treatments.
PMID:35439341 | DOI:10.1111/dth.15524
